ApoCell, Inc. Information

ApoCell was founded in 2004 as a spin out of MD Anderson Cancer Center by Dr. Darren Davis to commercialize translational contract research services for biopharma, academia and the government. ApoCell operates a CLIA certified laboratory to develop and conduct biomarker assays using clinical samples to facilitate which drugs benefit the right patients in an accelerated, cost-efficient manner. Our unique platform technologies facilitates a deeper understanding of the pharmacodynamics of investigational therapies enabling decisions to be made earlier in the drug development process. We use high content technologies like quantitative imaging, immunohistochemistry, flow cytometry and NGS to answer challenging research questions. We specialize in generating data to assess mechanism of action, optimize dosing schedules, identify biomarkers of resistance and sensitivity, facilitate patient stratification, and companion Dx development. ApoCell creates data driven solutions for our clients by integrating innovative platform technologies into complex work flows. ApoCell co-developed a proprietary platform technology, ApoStream®, with the NCI for isolating rare circulating tumor cells (CTCs) from blood. Our integrated approach allows us to investigate biomarkers using cutting-edge technologies in both ‘liquid biopsy’ and ‘tumor biopsy’ samples. ApoCell has accelerated drug development for some of the world’s largest and most innovative biopharma companies across different diseases including oncology and immuno-oncology, autoimmune and inflammatory, diabetes, infectious and regenerative medicine. We are always driven by the desire for more information, more insight, and more breadth and depth of analysis. We are a partner who will work with you to design customized assays using cutting edge technologies for optimal data generation. Together with our partners, we are dedicated and committed to improving the lives of patients with debilitating diseases.